Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBITDA (2020 - 2025)

Historic EBITDA for iSpecimen (ISPC) over the last 6 years, with Q3 2025 value amounting to -$2.8 million.

  • iSpecimen's EBITDA fell 9312.03% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year decrease of 2370.78%. This contributed to the annual value of -$12.5 million for FY2024, which is 1261.41% down from last year.
  • Latest data reveals that iSpecimen reported EBITDA of -$2.8 million as of Q3 2025, which was down 9312.03% from -$1.0 million recorded in Q2 2025.
  • Over the past 5 years, iSpecimen's EBITDA peaked at -$942644.0 during Q1 2021, and registered a low of -$6.0 million during Q4 2024.
  • For the 5-year period, iSpecimen's EBITDA averaged around -$2.4 million, with its median value being -$2.2 million (2023).
  • As far as peak fluctuations go, iSpecimen's EBITDA plummeted by 40114.78% in 2021, and later skyrocketed by 5034.56% in 2025.
  • Over the past 5 years, iSpecimen's EBITDA (Quarter) stood at -$2.0 million in 2021, then dropped by 7.35% to -$2.1 million in 2022, then tumbled by 34.06% to -$2.9 million in 2023, then plummeted by 110.62% to -$6.0 million in 2024, then surged by 54.01% to -$2.8 million in 2025.
  • Its last three reported values are -$2.8 million in Q3 2025, -$1.0 million for Q2 2025, and -$1.7 million during Q1 2025.